JP3886986B2 - Antiperspirant - Google Patents

Description

The present invention relates to an antiperspirant .

  Body odors such as scent, foot odor and sweat odor, which cause discomfort to the general public, are mainly caused by decomposition of a mixture of lipids such as sebum and sweat by skin resident bacteria. For example, vaginal odor is caused by the odor of fatty acids as lipid breakdown products contained in secretions secreted from apocrine sweat glands present in the axilla.

In order to prevent such body odor, conventional antiperspirants contain an antiperspirant component such as aluminum compounds such as aluminum hydroxychloride, aluminum chloride, chlorohydroxyaluminum zirconium, and zirconium compounds (for example, Patent Document 1 and Patent Document 2).

However, since these conventional antiperspirants use ingredients that are highly irritating to the skin, these antiperspirants are applied to areas sensitive to skin irritation such as wrinkles. When the content concentration of the component is increased, there is a problem that the skin tension becomes too high and the concentration cannot be increased, and there is a limit to the effect of preventing body odor.

  On the other hand, lysozyme is known as an enzyme having effects such as lysis and anti-inflammation, and a lysozyme-containing toiletry product has been proposed as a technique using this enzyme (Patent Document 3). However, Patent Document 3 is a technology relating to the stability of lysozyme, and does not describe the body odor preventing action relating to lysozyme.

JP 2002-3356 A JP 2002-47164 A Japanese Patent Laid-Open No. 1-283206

The present invention was made as a result of research and development based on such circumstances, and provides an antiperspirant that can be used not only for higher effects but also for areas sensitive to skin irritation. This is the issue.

The antiperspirant of the present invention contains at least lysozyme and vitamin E and / or a derivative thereof .

The antiperspirant of the present invention is also characterized in that the blending amount of vitamin E and / or its derivative is 0.0001 to 0.5% by weight .

Furthermore, the antiperspirant of the present invention is also characterized by the following points. That is,
( 1 ) The blending amount of lysozyme is 0.001 to 2.0% by weight when 150 mg (titer) of lysozyme chloride is used, and when lysozyme having a different titer from lysozyme chloride is used, It was set as the compounding quantity obtained by converting based on lysozyme.
( 2 ) The alpha-hydroxy acid was mix | blended as a stabilizer which stabilizes the enzyme activity of lysozyme.
( 3 ) The amount of α-hydroxy acid was 0.0001 to 1.0% by weight.
( 4 ) The α-hydroxy acid was citric acid.

According to the first aspect of the present invention, lysozyme is an enzyme that is also present in human body components such as tears, because it is an antiperspirant containing at least lysozyme and vitamin E and / or a derivative thereof . Since the irritation is low, even if it contains a required concentration of lysozyme, it can be used on a portion sensitive to skin irritation without irritation.

In particular, lysozyme, that provides reduction in the amount of sweat by converging action of pores, reduction of sweating due to a decrease in skin surface temperature caused by the reduction of blood flow caused by the converging action of the capillaries, etc. deodorizing action of lysozyme itself .

Therefore, not only the sweating amount and deodorizing action by lysozyme but also a synergistic effect of lysozyme and vitamin E or its derivative are brought about, and a higher body odor preventing effect is exhibited.

According to the second aspect of the present invention, the amount of vitamin E and / or a derivative thereof is 0.0001 to 0.5% by weight, thereby providing a sufficient body odor preventing effect while causing a synergistic effect with lysozyme. It can be set as the composition which plays.

According to the invention described in claim 3 , when 150 mg (titer) of lysozyme chloride is used, the amount of lysozyme is 0.001 to 2.0% by weight, and lysozyme having a titer different from that of lysozyme chloride is used. When it is used, the blending amount obtained by conversion based on lysozyme chloride can be used to achieve a blending effect sufficient for preventing body odor.

According to the invention described in claim 4 , by blending α-hydroxy acid as a stabilizer for stabilizing the enzyme activity of lysozyme, the enzyme activity of lysozyme is stabilized and the effect of preventing body odor by lysozyme is stably produced. The amount of lysozyme used can be reduced.

According to invention of Claim 5 , the enzyme activity of a lysozyme can be stabilized efficiently by the compounding quantity of (alpha) -hydroxy acid being 0.0001-1.0 weight%.

According to the invention described in claim 6 , by using α-hydroxy acid as citric acid, the enzyme activity of lysozyme can be stabilized at low cost.

The antiperspirant of the present invention is made by obtaining new knowledge that lysozyme has a strong antiperspirant action.

In other words, lysozyme has not only a conventionally known lysis effect, anti-inflammatory action, hemostatic action due to anti-heparin action, etc., but separately from these effects, a reduction in sweating due to the converging action of pores, It has been newly found that there is an action of reducing sweating due to a decrease in skin surface temperature due to a decrease in blood flow caused by a converging action of capillaries, and there is a deodorizing action by lysozyme itself.

Then, lysozyme is applied as an antiperspirant by paying attention to the effect of reducing the sweating amount and the deodorizing effect.

  In particular, lysozyme is not only capable of preventing body odor due to these antiperspirant and deodorant effects, but also has a remarkable effect that it is less irritating to the skin because it is an enzyme present in human body components. Even if a required concentration of lysozyme is applied to a part sensitive to skin irritation, the part can be used without irritation.

  The lysozyme that is generally distributed as lysozyme chloride is easy to use, but is not limited to lysozyme chloride, and may be one fixed to an appropriate carrier.

  The blending amount of lysozyme is 0.001 to 2.0% by weight when 150 mg (titer) of lysozyme chloride is used. When lysozyme having a titer different from that of lysozyme chloride is used, the amount is 0.001 to 2.0% by weight when converted based on lysozyme chloride. The titer of lysozyme was measured by the method described in the section of lysozyme chloride on the basis of cosmetic raw materials.

  Lysozyme fixed to an appropriate carrier has higher enzyme activity stability than lysozyme alone, and can be used in a smaller amount than lysozyme chloride.

  By blending the amount of lysozyme into 0.001 to 2.0% by weight in terms of 150 mg (titer) of lysozyme chloride, a formulation that exhibits a sufficient body odor prevention effect while suppressing the amount of lysozyme chloride used can do.

  If the amount of lysozyme is less than 0.001% by weight, the required body odor prevention effect cannot be obtained, and if it exceeds 2.0% by weight, a further effect can be expected. Absent. Therefore, the blending amount of lysozyme is 0.001 to 2.0% by weight when 150 mg (titer) of lysozyme chloride is used. In addition, More preferably, it is 0.1 to 0.5 weight%.

The antiperspirant of the present invention is a body odor preventing agent containing at least lysozyme and vitamin E and / or a derivative thereof.

  That is, by adding vitamin E and / or a derivative thereof to lysozyme, not only a reduction in sweating and a deodorizing effect by lysozyme, but also a synergistic effect between lysozyme and vitamin E or a derivative thereof is achieved to improve the body odor prevention effect. be able to.

In particular, since vitamin E and / or its derivatives can improve the body odor prevention effect of lysozyme, it is possible to reduce the concentration of conventional antiperspirant components such as aluminum chloride that have an irritant property and have high safety. Can be antiperspirant .

  The blending amount of vitamin E and / or derivatives thereof is 0.0001 to 0.5% by weight, so that a sufficient synergistic effect with lysozyme can be produced to improve the body odor prevention effect. be able to.

  When the blending amount of vitamin E and / or its derivative is less than 0.0001% by weight, an improvement effect on the body odor prevention effect of lysozyme cannot be expected, and when blending more than 0.5% by weight, I cannot expect any more effect. Therefore, the blending amount of vitamin E and / or a derivative thereof is set to 0.0001 to 0.5% by weight. In addition, More preferably, it is 0.001-0.1 weight%.

  As vitamin E, α-tocopherol, β-tocopherol, γ-tocopherol, σ-tocopherol, natural vitamin E and the like can be used, and as derivatives of vitamin E, tocopherol acetate, tocopherol nicotinate, α-tocopherol-2 -L-ascorbic acid diester or the like can be used. In addition, vitamin E and its derivative may be any of d-form, l-form, and dl-form.

Furthermore, in the above antiperspirant , when α-hydroxy acid is added as a stabilizer for stabilizing the enzyme activity of lysozyme, the enzyme activity of lysozyme is stabilized and the body odor prevention effect by lysozyme is stably produced. The amount of lysozyme used can be reduced.

  In particular, the enzyme activity of lysozyme can be efficiently stabilized by setting the blending amount of α-hydroxy acid to 0.0001 to 1.0% by weight. When the blending amount of the α-hydroxy acid is less than 0.0001% by weight, the effect of stabilizing the activity of lysozyme by addition cannot be expected, and when it exceeds 1.0% by weight, the activity of lysozyme is reduced. May interfere. Therefore, the blending amount of α-hydroxy acid is set to 0.0001 to 1.0% by weight. In addition, More preferably, it is 0.001-0.1 weight%.

  Furthermore, when α-hydroxy acid is citric acid, the enzyme activity of lysozyme can be stabilized at low cost.

  The α-hydroxy acid is not necessarily limited to citric acid, and glycolic acid, lactic acid, glyceric acid, malic acid, tartaric acid and the like can be used instead of citric acid.

The above antiperspirant may further contain an antiperspirant component or a surfactant.

When an antiperspirant component is contained in the antiperspirant, the body odor prevention effect of lysozyme can be synergistically improved.

  The content of the antiperspirant component is preferably contained at a concentration that does not cause irritation to a part sensitive to skin irritation, and is 0.001 to 5.0% by weight. When the content of the antiperspirant component is less than 0.001% by weight, a synergistic effect with the body odor prevention effect of lysozyme cannot be expected. Not only can the effect not be expected, but the skin may become more tight and may cause skin irritation. Therefore, the content of the antiperspirant component is set to 0.001 to 5.0% by weight. In addition, More preferably, it is 0.1 to 2.0 weight%.

  Antiperspirant components include, for example, aluminum chloride, potassium aluminum sulfate, aluminum sulfate, aluminum acetate, chlorohydroxyaluminum, allantoin chlorohydroxyaluminum, aluminum / zirconium chlorohydrate / glycine complex, zinc paraphenolsulfonate, benzalkonium chloride Benzethonium chloride, halocarban, trichlorocarbanilide, chlorhexidine hydrochloride, isopropylmethylphenol, triclosan, chlorhexidine gluconate, zinc oxide, alkyldiethanolamide and the like. Of these, aluminum chloride, potassium aluminum sulfate, aluminum sulfate, aluminum acetate, chlorohydroxyaluminum, allantoinchlorohydroxyaluminum, aluminum / zirconium chlorohydrate / glycine complex, zinc paraphenolsulfonate, etc. are preferably used. More preferably, hydroxyaluminum is used. These antiperspirant components can be used singly or in combination of two or more.

When a surfactant is blended in the antiperspirant of the present invention, it is possible to improve the drug effect maintenance time while suppressing the occurrence of non-uniformity of each drug in the antiperspirant . Although the compounding quantity of surfactant is not specifically limited, It is 0.01 to 10 weight%, More preferably, it is 0.1 to 5.0 weight%.

  The surfactant to be used is not particularly limited, and any of a nonionic surfactant, an anionic surfactant, a cationic surfactant, and an amphoteric surfactant can be used.

  Examples of the nonionic surfactant include sorbitan fatty acid ester, glycerin fatty acid ester, castor oil, hydrogenated castor oil, and alkylene oxide adducts thereof, polyglycerin fatty acid ester, polyoxyalkylene alkyl ether, polyoxyalkylene fatty acid ester. , Polyoxyalkylene alkylphenol, polyoxyethylene sorbite fatty acid ester, polyoxyethylene alkylphenyl formaldehyde condensate, polyoxyethylene sterol and its derivatives, polyoxyethylene lanolin and its derivatives, polyoxyethylene beeswax derivatives, sugar esters, etc. can do.

  Examples of the anionic surfactant include higher fatty acid soaps, alkyl sulfate esters, alkyl phosphates, polyoxyethylene alkyl ether sulfates, polyoxyethylene alkyl phenyl ether sulfates, alkyl ether phosphates, alkyl ethers. Carboxylate, acylmethyl taurate, N-acyl-N-methyl-β-alanine, N-acyl glycine, N-acyl glutamate, polyoxyethylene alkyl carboxylate, alkylphenyl ether sulfonate, alkyl Examples thereof include sulfosuccinic acid and its salt, N-acyl sarcosine and its salt, polyoxyethylene coconut oil fatty acid monoethanolamide sulfate and the like.

  Examples of the cationic surfactant include amine salts such as alkylamine salts, fatty acid amide amine salts, ester-containing tertiary amine salts; monoalkyl type quaternary ammonium salts, dialkyl type quaternary ammonium salts, trialkyl type quaternary salts. Examples include ammonium quaternary ammonium salts such as benzalkonium-type quaternary ammonium salts; cyclic quaternary ammonium salts such as alkyl pyridinium salts; benzethonium chloride and the like.

  Examples of the amphoteric surfactant include glycine-type amphoteric surfactants such as alkyl glycine salt, carboxymethyl glycine salt, N-acylaminoethyl-N-2-hydroxyethyl glycine salt; alkylaminopropionate, alkyliminodi Aminopropionic acid type amphoteric surfactants such as propionate; aminoacetic acid betaine type amphoteric surfactants such as alkyldimethylaminoacetic acid betaine and fatty acid amidopropyldimethylaminoacetic acid betaine; sulfobetaine type amphoteric surfactants such as alkylhydroxysulfobetaine An agent etc. can be illustrated.

  Of these, nonionic surfactants are preferably used, and more preferably, alkylene oxide adducts, that is, alkylene oxide adducts of sorbitan fatty acid ester, glycerin fatty acid ester, castor oil, and hydrogenated castor oil are used. In the present invention, it is particularly preferable to use polyoxyethylene hydrogenated castor oil from the viewpoint of safety to the skin and stability to lysozyme.

The above antiperspirants further include lower alcohols such as ethanol; silicones such as dimethylsiloxane; higher alcohols such as stearyl alcohol; thickeners such as hydroxyethyl cellulose and carboxyvinyl polymer; 1,3-butylene glycol Polyhydric alcohols such as glycerin; preservatives such as paraben, phenoxyethanol and 1,2-pentanediol; powders, animal and plant extracts, pH adjusters, colorants, water, propellants and the like can be appropriately blended.

  And it can use for various forms, such as a lotion, an aerosol, a stick, powder, roll-on, a cream, and an emulsion, About a formulation, it can manufacture with a generally known manufacturing method.

  Hereinafter, the present invention will be described in more detail based on examples. In addition, this invention is not limited at all by these Examples. Unless otherwise specified, the blending amount is% by weight.

[Reference Example 1]
(Sample preparation)
According to the composition described in Table 1 below, each sample of a2, b2, and c2 was prepared by a standard method, and the following lysozyme for pore convergence, blood flow suppression, skin hardening, antiperspirant, and odor suppression Each action for preventing body odor was evaluated. Incidentally, a2 the body smell inhibitor you containing lysozyme, b2 conventional deodorants containing no lysozyme, c2 represents a base other than the active ingredient to prevent body odor from both deodorants.

In addition, although lysozyme chloride can be normally manufactured from egg white, in this reference example , a trade name: lysozyme chloride (manufactured by Kewpie Co., Ltd.) was used. The product name may be lysozyme chloride (manufactured by Eisai Co., Ltd.).

(Test Example 1: Pore converging action)
It carried out as follows with respect to the test subject of 20 men and women. That is, the subject is laid on a bed, a microscope (manufactured by SCARA Co., Ltd.) is brought into contact with the subject's heel to determine an appropriate pore, and an image obtained by photographing the pore is taken into a computer. 50 μl of the test solution is injected into the pores, and images of pores obtained by photographing after 2 to 3 minutes are taken. The images of pores before and after the injection of the subject are compared with the naked eye to determine the degree of convergence of the pores. The scores were scored according to the criteria.
<Criteria>
Conspicuously converged 5 points Converged 4 points Converged to some extent 3 points Not converging 2 points Not converged 1 point

FIG. 1 is a histogram diagram of the obtained results. As apparent from FIG. 1, the average value of the pore convergence, body odor inhibitor (a2) in 2.8, in the conventional deodorants (b2) 2.1, the base was 2.05.

That is, while the conventional body odor preventive agent and the base have the same pore convergence effect, the body odor preventive agent containing lysozyme has a significantly higher pore convergence effect than the conventional body odor preventive agent. Therefore, it was found that lysozyme clearly has a pore converging effect.

(Test Example 2: Blood flow suppression effect)
It carried out as follows with respect to the test subject of 20 men and women. That is, the subject was seated on a chair and allowed to rest for 5 minutes before the start of the test, and then a sensor of a laser Doppler meter DRT4 (manufactured by Moor Instruments Ltd) was attached to the middle finger of the subject, and the initial blood flow was measured.

  Next, 1 ml of the test solution is applied to the middle finger of the subject from which the sensor has been temporarily removed from a position separated by a distance of 10 cm, the change in blood flow is measured over time, and the relative value to the initial blood flow is determined. Obtained.

  FIG. 2 is a line graph of the obtained results. As is clear from FIG. 2, the average relative value of the blood flow is almost changed for 30 minutes until the measurement is completed in the base (c2). On the other hand, with the conventional body odor preventing agent (b2), it gradually decreased to 0.83, which is a substantially bottom value, for 4 minutes after spraying, and gradually increased until 30 minutes when the measurement was completed.

On the other hand, in the body odor preventing agent (a2) containing lysozyme, the average relative value of the blood flow rapidly decreases immediately after spraying, and reaches about 0.68 which is a substantially bottom value after about 2 minutes. It was 0.77 even 30 minutes after finishing.

  Therefore, it was found that lysozyme clearly has a blood flow suppression effect.

(Test Example 3: Skin hardening effect)
It carried out as follows with respect to the test subject of 20 men and women. That is, a target area of 3 cm × 3 cm was set on the left and right eyelids of the subject, a test liquid was applied to one target area to be an application area, and a control area in which the test liquid was not applied to the other target area.

  After measuring the initial skin hardening in both regions with Piera (manufactured by Tanita Co., Ltd.), 100 μl of the test solution was applied to the application region, and changes in skin hardening were measured over time.

  FIG. 3 is a line graph of the obtained results. As is clear from FIG. 3, the hardening of the skin is hardly changed in the base (c2) for 30 minutes until the measurement is completed. Moreover, in the conventional body odor preventer (b2), it was raised (hardened) by about 0.5.

On the other hand, in the body odor preventive agent (a2) containing lysozyme , the hardening of the skin rose from 9.5 immediately after application to 8.2 which is a substantially bottom value, and 30 minutes after the measurement was completed. However, it was 8.7 harder than the conventional body odor preventive agent.

  Therefore, it was found that lysozyme clearly has a skin hardening effect.

(Test Example 4: Antiperspirant action)
It carried out as follows with respect to the test subject of 20 men and women.

(1) Measurement of normal sweating A water-absorbing pad (trade name: Ashiwaki pad, manufactured by Kobayashi Pharmaceutical Co., Ltd.) is sandwiched between both sides of the subject, and both water-absorbing pads are discarded after 40 minutes and immediately weighed in advance. The water-absorbing pads that were measured were sandwiched between both sides for 20 minutes, the weights of both water-absorbing pads were measured, and the increased weight was taken as the amount of sweating.

  This operation was performed once a day for 3 days, and the average value of these three sweat amounts was defined as the normal sweat amount (n).

(2) Measurement of sweating action 2-1) Day 1 and day 4 Approximately 0.5 ml of the test solution was sprayed from both positions of the subject from a position separated by a distance of 10 cm.
2-2) 2nd day, 3rd day, and 5th day As in the 1st day, spray the body odor preventive agent on both sides of the subject and let it dry naturally for 30 seconds. After 40 minutes, both absorptive pads were discarded. Immediately after the water absorbent pads previously weighed were sandwiched between both sides for 20 minutes, the weight of both water absorbent pads was measured and increased. The weight was defined as the amount of sweat (m).

  And the difference between this sweating amount (m) and the above-mentioned normal sweating amount (n) was taken, and the sweating inhibition rate with respect to the normal sweating amount (n) was calculated | required from the following formula.

  In addition, in the test subject, the use of the antiperspirant was stopped one week before the start of this test, and when the amount of sweating was measured, the room was allowed to act freely except for intense work and exercise.

  FIG. 4 is a histogram of the results obtained. As is apparent from FIG. 4, the average value of the sweat inhibition rate is higher on the third day than on the second day in the base (c2). The third day and the fifth day were almost the same.

  Moreover, in the conventional body odor prevention agent (b2), the average value of the perspiration suppression rate is higher than that of the base (c2) regardless of the measurement day, and the degree of the increase is relative to the second day. The third day was a relatively large result, but the fifth day was smaller than the third day.

On the other hand, in the body odor preventive agent (a2) containing lysozyme, the degree of increase in the average value of the antiperspirant rate is about the same as that of the conventional body odor preventive agent on the third day compared to the second day. However, the 5th day compared to the 3rd day is larger than the case of the conventional body odor preventing agent, and the average value of the antiperspirant rate on the 5th day is higher than the average value of the antiperspirant rate of the conventional body odor preventing agent. It was a big value.

  Therefore, it was found that lysozyme clearly has an antiperspirant effect. On the other hand, the average value of the antiperspirant rate has increased with the passage of time, and it has been found that the antiperspirant action is increased over the conventional body odor preventive agent by continuous use of the body odor preventive agent.

(Test Example 5: Odor control effect)
2 ml of the test solution was injected into a sample bottle with a capacity of 10 ml, and isovaleric acid solution as the target odor liquid 1 and 150 μl of n-butyric acid solution as the target odor liquid 2 were added.

  Thereafter, the mixture was sufficiently stirred and heated at 37 ° C. for 30 minutes. 100 μl of liquid was collected from the sample bottle, and dropped on eight-cut filter paper (Toyo Filter Paper No. 125) previously put in an Erlenmeyer flask.

  The Erlenmeyer flask was sealed, heated at 37 ° C. for 30 minutes for vaporization, and the odor concentration in the gas was measured with a gas detector (No. 81, manufactured by Gastec Corporation).

  FIG. 5 is a histogram of odor suppression results for the target odor liquid 1 (isovaleric acid), and FIG. 6 is a histogram of odor suppression results for the target odor liquid 2 (n-butyric acid), which is apparent from FIGS. 5 and 6. As described above, the base (c2) and the conventional body odor preventer (b2) did not have an inhibitory effect on both target odors, and a certain concentration of odor was generated.

On the other hand, in the body odor preventing agent (a2) containing lysozyme, the concentration of both target odors is lower than both the base and the conventional body odor preventing agent.

  Therefore, it was found that lysozyme clearly has an odor suppressing action.

(Test Example 6: Body odor prevention effect)
It carried out as follows with respect to the test subject of 20 men and women. That is, after the subject was sprayed with an appropriate amount of the test solution for 2 weeks, the odor level of the sprayed portion was sensory-evaluated.

Evaluation was scored according to the following criteria. The test was carried out by the double blind method.
<Criteria>
No smell at all 5 points No smell at all 4 points Little smell at all 3 points No change 2 points No change 1 point

  FIG. 7 is a histogram of the obtained results. As is clear from FIG. 7, the average score of the body odor prevention effect is 1.7 for the base (c2), and the body odor preventive agent of the present invention ( a2) was 2.8.

  Moreover, in the conventional body odor prevention agent (b2), it is 2.4, and the body odor prevention agent of the present invention is more excellent in body odor prevention effect and exhibited a high body odor prevention effect.

In addition, although the test of the body odor prevention effect showed the result performed about the test subject's sputum, it cannot be overemphasized that the body odor prevention agent containing a lysozyme exhibits the object prevention effect also about the other site | part of a test subject.

(Sample preparation)
According to the composition described in Table 2 below, samples a1, b1, and c1 were prepared by conventional methods. In addition, each sample of a1-c1 is corresponded to what mix | blended vitamin E with each sample of a2-c2 of the reference example 1. FIG.

(Test example)
About each sample of said a1-c1, it evaluated similarly to the reference example 1 about each function of a pore convergence effect | action, a blood flow rate suppression effect | action, a skin effect effect | action, an antiperspirant effect | action, an odor suppression effect | action, and a body odor prevention effect. The obtained results are shown in FIGS. In addition, each result regarding a2-c2 of the reference example 1 was also described collectively for the comparison.

  As is clear from FIGS. 8 to 14, in the base (c1) and the conventional body odor preventing agent (b1), the effect of adding vitamin E was not recognized in any case.

On the other hand, in the antiperspirant (a1) according to the present invention, it was recognized that in any case, the above-mentioned actions were further enhanced by the addition of vitamin E.

It is a histogram which shows the result of having tested the pore converging effect of lysozyme. It is a line graph which shows the result of having tested the blood flow volume inhibitory effect of lysozyme. It is a line graph which shows the result of having tested the skin hardening effect | action of lysozyme. It is a histogram which shows the result of having tested the antiperspirant effect of lysozyme. It is a histogram which shows the result of having tested the odor suppression effect with respect to isovaleric acid of a lysozyme. It is a histogram which shows the result of having tested the odor suppression effect with respect to n-butyric acid of a lysozyme. It is a histogram which shows the result of having tested the body odor prevention effect of lysozyme. It is a histogram which shows the result of having tested the addition effect of vitamin E with respect to the pore converging effect of a lysozyme. It is a line graph which shows the result of having tested the addition effect of vitamin E with respect to the blood flow volume inhibitory effect of a lysozyme. It is a line graph which shows the result of having tested the addition effect | action of vitamin E with respect to the skin hardening effect | action of lysozyme. It is a histogram which shows the result of having tested the addition effect of vitamin E with respect to the antiperspirant effect of a lysozyme. It is a histogram which shows the result of having tested the odor suppression effect with respect to the addition effect of the vitamin E with respect to the isovaleric acid of a lysozyme. It is a histogram which shows the result of having tested the odor suppression effect with respect to the addition effect of the vitamin E with respect to n-butyric acid of a lysozyme. It is a histogram which shows the result of having tested the addition effect of the vitamin E with respect to the body odor prevention effect of a lysozyme.

Claims (6)

An antiperspirant containing at least lysozyme and vitamin E and / or a derivative thereof. The antiperspirant according to claim 1, wherein the amount of vitamin E and / or its derivative is 0.0001 to 0.5% by weight. The amount of the lysozyme is 0.001 to 2.0% by weight when 150 mg (titer) of lysozyme chloride is used, and when lysozyme having a different titer from the lysozyme chloride is used, The antiperspirant according to claim 1 or 2, characterized in that the blending amount is obtained by conversion based on lysozyme. The antiperspirant according to any one of claims 1 to 3, wherein an α-hydroxy acid is added as a stabilizer for stabilizing the enzyme activity of the lysozyme. The antiperspirant according to claim 4, wherein the amount of the α-hydroxy acid is 0.0001 to 1.0% by weight. The antiperspirant according to claim 4 or 5, wherein the α-hydroxy acid is citric acid.

Images